A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

Phase 1 Completed 77 enrolled Viatris Innovation GmbH

RandomizedParallel-groupTriple-blindOther

Summary

The primary objective of this study is to assess the pharmacodynamic (PD) effects of clopidogrel, prasugrel, and ticagrelor when administered after a single subcutaneous (s.c.) dose of ACT-246475 in healthy male and female subjects

Timeline

Start: 2018-01-24
Primary completion: 2019-05-20
Completion: 2019-05-29

Publications

Results Schilling U, Dingemanse J, Dobrow M, Baumann M, Riederer MA, Juif PE, Ufer M. Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor. Thromb Haemost. 2021 Jun;121(6):755-766. doi: 10.1055/s-0040-1721773. Epub 2021 Jan 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Clopidogrel	Small molecule	300 mg	Oral
Subject	Clopidogrel	Small molecule	600 mg	Oral
Subject	Prasugrel	Small molecule	60 mg	Oral
Subject	Selatogrel	Small molecule	16 mg	Subcutaneous
Subject	Ticagrelor	Small molecule	180 mg	Oral

Indications

No indication recorded.